Improving Remission in MDD: Focus on Augmentation Strategies CME

Ian A. Cook, MD Author Information and Disclosures

Release Date: April 18, 2008; Valid for credit through April 18, 2009

Credits Available
Physicians - maximum of 0.5 AMA PRA Category 1 Credit(s)™ for physicians

This CME activity was designed as a Test and Teach program for release on Medscape.

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the educational content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright © 2008 CME LLC
BMS, Otsuka
Learning Objectives
Upon completion of this activity, participants should be able to:
  1. Describe how patients receiving pharmacotherapy for depression should be monitored systematically for changes in symptoms as well as medication side effects.
  2. Identify how augmentation of an antidepressant medication with another agent can be used to convert a partial response to a more complete remission.
  3. Explain how long-term management of depression may require changes in treatment strategy over time.
Author Disclosures
Ian A. Cook, MD
Disclosure: Grant/Research Support: Aspect Medical Systems, Cyberonics, Inc., Eli Lilly and Company, MedAvante, Novartis Pharmaceuticals Corporation, Sepraprar, Pfizer Inc, Vivometrics; Consultant: Ascenda Media, Bristol-Myers Squibb Company, Cyberonics, Inc., Forest Laboratories, Janssen, L.P; Speakers' Bureau: Bristol-Myers Squibb Company, Wyeth Pharmaceuticals
 
CME
CME LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME LLC designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME credits from activities presented by ACCME accredited providers may be used toward American Osteopathic Association (AOA) Category 2-A requirements.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.